This memo issues no Long / Short / Watchlist / Avoid verdict. It scores every Criteria and blocks on none of them. Whether the analysis justifies a position is a question about a particular book, and the book decides.
How to read this
This is an analysis, not a position. The memo scores every Criteria and blocks on none of them. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently — so this page carries no Long, Short, Watchlist or Avoid verdict.
Every Criteria returns PASS / FAIL / INDETERMINATE, and carries a type. BINDING criteria are admission tests for a long-only absolute-return strategy. MEASURED criteria are always scored and stored, and never block — they inform timing, sizing or a future strategy. A missing input is INDETERMINATE, never FAIL.
Two valuation outputs, over two horizons. The implied-path test (reverse DCF) asks what today's price requires over five years and whether the business has demonstrated it; the 12-month target asks what the name is likely to trade at, on near-term estimates and the name's own multiple history with its percentile stated. Neither replaces the other. Sensitivity is run over the exit multiple, never over scenario probabilities.
Momentum is entry timing only. It governs when to enter a position the thesis already justifies, never whether to own one.
Key findings
- MATERIAL EVENT THE SCREEN MISSED: NBIX completed a $2.9bn all-cash acquisition of Soleno Therapeutics on 2026-05-18, funded in part by a $600m draw on a new $1.0bn SECURED revolver with a security interest over substantially all assets. Net cash went from $2,647.2m to roughly $226m. Any valuation treating NBIX as a $2.65bn-net-cash company is now wrong.
- ACCOUNTING QUALITY: revenue is the cleanest in the batch - 98.2% gross margin, 99.1% product sales, no settlement or milestone revenue, FY2025 operating cash flow $782.7m against net income $478.6m.
- ACCOUNTING QUALITY - THE REAL FINDING: operating leverage went NEGATIVE in FY2025. Revenue +21.4%, non-GAAP diluted EPS +0.9% ($6.33 to $6.39). GAAP EPS rose 41.9% only because FY2024 carried a $138.4m non-recurring convertible-note settlement charge. R&D rose 38.9% to 35.5% of revenue.
- ACCOUNTING QUALITY: Q1 2026 GAAP net income of $197.9m includes $28.6m from the sale of Neurocrine Group Limited and a $25.3m unrealised equity-investment gain - $53.9m, or 27%. Both are correctly excluded from non-GAAP, so non-GAAP EPS of $1.94 is clean.
- CAPITAL ALLOCATION: NBIX paid ~10.2x trailing sales for Soleno. VYKAT XR's sequential growth in the last quarter filed before close (Q1 2026, filed 8 days before the tender expired) was +3.2%, against +102% and +39% in the two prior quarters. Soleno withdrew its EU marketing application the day after the deal was announced.
- MECHANISM: a funded de-concentration away from a product that is still 84.6% of trailing revenue. CRENESSITY ramped 14.5 -> 53.2 -> 98.1 -> 135.3 -> 153.3 ($m/quarter) with ~80% reimbursement; INGREZZA re-accelerated to +20.5% in Q1'26 because the usual Q1 gross-to-net step-down did not happen (Q1'25 fell 11.4% sequentially; Q1'26 was flat).
- PRODUCT CYCLE: osavampator's economics were converted in January 2025 from a 50/50 Takeda profit share to a royalty-bearing licence at mid-to-upper-teens US royalties, with Japan rights returned. No memo should model it at full economics.
- PATENT: INGREZZA generic entry is SETTLED to 1 March 2038 for the original ANDA filers, so a five-year implied path sits entirely inside exclusivity. The live exposure is Zydus, which filed against INGREZZA SPRINKLE in March 2025 and is not party to those settlements.
- MENTION FREQUENCY: 'schizophrenia' rises monotonically from 3.9 to 12.2 per 10k words and holds for five quarters - corroborated by direclidine entering Phase 3, NBI-1117570 entering Phase 2 in March 2026, and a $22.5m milestone expensed on that initiation. 'Soleno', 'VYKAT' and 'Prader-Willi' are first-ever mentions in 2026Q1 - an entire franchise appearing from zero.
- VALUATION CAVEAT: the +14.5pp margin is entirely attributable to CRENESSITY and VYKAT XR growing into the mix. On INGREZZA alone the required path is NOT cleared (-1.1pp on FY2025 growth, -0.4pp on FY2026 guidance).
Sections
Disclosed limitations
- The pro-forma post-Soleno balance sheet is an ESTIMATE built from five separately filed components and labelled as such everywhere it is used. The Q2 2026 10-Q, expected within days, replaces it with a filed number.
- No Soleno purchase accounting exists yet - no goodwill, no intangibles, no inventory fair-value step-up. Given what that same step-up did to GMED's reported margins in this batch, it is the single most important unfiled number in the file.
- No Street consensus anywhere in this memo - Alpha Vantage EARNINGS_ESTIMATES quota was exhausted on 2026-07-29 and the API returned its rate-limit notice. Every forward figure is company guidance (labelled) or a house estimate (labelled).
- NBIX guides INGREZZA only. There is no company guidance for CRENESSITY, VYKAT XR or total revenue; the FY2026/FY2027 revenue build is shown line by line with each line labelled GUIDANCE or HOUSE, and the house lines are ~41% of the FY2027 total.
- Mention-frequency was run on the SEC EDGAR 8-K Ex-99.1 quarterly earnings-release corpus (13 quarters, 2023Q1-2026Q1), not Alpha Vantage transcripts. One source used consistently across the whole series, per references/mention-frequency.md.
- No probability-weighted pipeline value. osavampator and direclidine are Phase 3 with NO disclosed topline dates; they are described qualitatively and excluded from every valuation output.
- No trial date, Markman date or 30-month-stay expiry for the Zydus litigation appears in any NBIX filing reviewed, so none is stated. The D. Delaware PACER docket is the obvious next research step and is outside what this memo could retrieve.
- Q2 2026 has not been reported. The latest hard data is Q1 2026 (filed 2026-05-05), and this memo is being written within days of a print that changes several of its inputs.
- Operating lease liabilities of ~$470m (current + non-current) are NOT in enterprise value; a book that capitalises leases should add ~$4.67 per share of EV.
- Consolidated ADV is not available from the Alpaca IEX feed; only the partial-tape figure ($11.6m/day) is reported, labelled as partial.